IN2012DN06629A - - Google Patents

Info

Publication number
IN2012DN06629A
IN2012DN06629A IN6629DEN2012A IN2012DN06629A IN 2012DN06629 A IN2012DN06629 A IN 2012DN06629A IN 6629DEN2012 A IN6629DEN2012 A IN 6629DEN2012A IN 2012DN06629 A IN2012DN06629 A IN 2012DN06629A
Authority
IN
India
Prior art keywords
formulations
aav
superior
methods
clinical use
Prior art date
Application number
Other languages
English (en)
Inventor
John Fraser Wright
Guang Qu
Bernd Hauck
Katherine High
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of IN2012DN06629A publication Critical patent/IN2012DN06629A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01064—Retinoid isomerohydrolase (3.1.1.64)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing & Machinery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN6629DEN2012 2010-01-28 2011-01-25 IN2012DN06629A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29918410P 2010-01-28 2010-01-28
PCT/US2011/022371 WO2011094198A1 (fr) 2010-01-28 2011-01-25 Plateforme de fabrication évolutive pour purification de vecteurs viraux et vecteurs viraux ainsi purifiés utilisables en thérapie génique

Publications (1)

Publication Number Publication Date
IN2012DN06629A true IN2012DN06629A (fr) 2015-10-23

Family

ID=44319714

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6629DEN2012 IN2012DN06629A (fr) 2010-01-28 2011-01-25

Country Status (14)

Country Link
US (4) US9408904B2 (fr)
EP (1) EP2529020B1 (fr)
JP (4) JP2013517798A (fr)
CN (2) CN105838737A (fr)
AU (1) AU2011209743B2 (fr)
BR (1) BR112012018899A2 (fr)
CA (1) CA2787827C (fr)
DK (1) DK2529020T3 (fr)
ES (1) ES2680915T3 (fr)
IL (1) IL221158B (fr)
IN (1) IN2012DN06629A (fr)
MX (1) MX340102B (fr)
PT (1) PT2529020T (fr)
WO (1) WO2011094198A1 (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
EP2529020B1 (fr) * 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia Plateforme de fabrication évolutive pour purification de vecteurs viraux et vecteurs viraux ainsi purifiés utilisables en thérapie génique
CA3066596A1 (fr) 2010-04-23 2011-10-27 University Of Massachusetts Vecteurs aav ciblant le systeme nerveux central et leurs procedes d'utilisation
CA2833905C (fr) 2010-04-23 2019-09-10 University Of Massachusetts Constructions d'expression a cistrons multiples
DK2744895T3 (en) * 2011-09-08 2016-01-04 Uniqure Ip Bv REMOVAL OF INFECTED VIRA FROM AAV PREPARATIONS
FR3002237B1 (fr) * 2013-02-15 2017-12-15 Genethon Methodes pour la production de particules virales aav double brin
EP3415620B1 (fr) 2013-11-26 2021-03-31 The United States of America, as represented by The Secretary, Department of Health and Human Services Vecteurs de type virus adéno-associé pour le traitement de maladie du stockage du glycogène
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
WO2015127128A2 (fr) 2014-02-19 2015-08-27 University Of Massachusetts Vaa recombinants ayant des propriétés de transcytose utiles
WO2015143078A1 (fr) 2014-03-18 2015-09-24 University Of Massachusetts Compositions à base de virus adéno-associé recombinant raav et méthodes de traitement de la sclérose latérale amyotrophique
FI3628334T3 (fi) * 2014-03-21 2023-09-15 Genzyme Corp Geenihoito verkkokalvon pigmenttirappeuma
CA2946392A1 (fr) 2014-04-25 2015-10-29 James M. Wilson Variants de ldlr et leur utilisation dans des compositions permettant de reduire les taux de cholesterol
EP3134522B1 (fr) * 2014-04-25 2021-10-06 University of Massachusetts Vecteurs de virus adéno-associés recombinants utiles pour réduire une immunité contre des produits transgéniques
US10689653B2 (en) 2014-06-03 2020-06-23 University Of Massachusetts Compositions and methods for modulating dysferlin expression
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
EP3200830B1 (fr) 2014-10-03 2020-09-09 University of Massachusetts Vecteurs aav identifiés au moyen de banques à efficacité élevée
RU2738421C2 (ru) 2014-10-21 2020-12-14 Юниверсити Оф Массачусетс Варианты рекомбинантных aav и их применения
PL3224376T5 (pl) * 2014-11-28 2023-08-21 Uniqure Ip B.V. Zanieczyszczenia DNA w kompozycji zawierającej wiriony parwowirusowe
ES2824829T3 (es) 2014-12-23 2021-05-13 Us Health Vectores de virus adenoasociado que codifican G6PC modificada y usos de estos
SG11201704919SA (en) 2015-01-13 2017-07-28 Alfa Wassermann Inc Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav)
EP3054007A1 (fr) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Purification de particules de virus adéno-associés de recombinaison comprenant une étape de purification par affinité immunologique
EP3054006A1 (fr) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Purification de particule de virus adéno-associé recombinant avec une chromatographie à échange d'anions en plusieurs étapes
US10584321B2 (en) 2015-02-13 2020-03-10 University Of Massachusetts Compositions and methods for transient delivery of nucleases
WO2016137949A1 (fr) * 2015-02-23 2016-09-01 Voyager Therapeutics, Inc. Expression régulable au moyen du virus adéno-associé (vaa)
US10058624B2 (en) 2015-04-16 2018-08-28 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
PT3285813T (pt) 2015-04-23 2021-03-05 Univ Washington State Administração do gene smad7 como um produto terapêutico
CA3021949C (fr) 2015-04-24 2023-10-17 University Of Massachusetts Constructions d'aav modifiees et utilisations de celles-ci
WO2017070516A1 (fr) 2015-10-22 2017-04-27 University Of Massachusetts Vecteurs du sérotype de virus adéno-associés ciblant la prostate
WO2017070525A1 (fr) 2015-10-22 2017-04-27 University Of Massachusetts Procédés et compositions pour le traitement du déséquilibre métabolique dans une maladie neurodégénérative
CN105420275A (zh) * 2015-11-27 2016-03-23 中国科学院苏州生物医学工程技术研究所 制备外源功能基因定点整合的人神经干细胞的方法
WO2017100704A1 (fr) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Procédé de purification évolutif d'aavrh10
WO2017160360A2 (fr) 2015-12-11 2017-09-21 The Trustees Of The University Of Pennsylvania Méthode de purification évolutive pour virus adéno-associé 9 (aav9)
EP4215605A1 (fr) 2015-12-11 2023-07-26 The Trustees of The University of Pennsylvania Procédé de purification évolutif d'aav8
US11015173B2 (en) * 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
CN115957350A (zh) * 2015-12-11 2023-04-14 宾夕法尼亚州大学信托人 用于治疗家族性高胆固醇血症的基因疗法
CA3008413A1 (fr) 2015-12-18 2017-06-22 Sangamo Therapeutics, Inc. Disruption ciblee du recepteur des lymphocytes t
EA201891212A1 (ru) 2015-12-18 2019-01-31 Сангамо Терапьютикс, Инк. Адресная дезорганизация клеточного рецептора гкгс
EP3411056A4 (fr) 2016-02-02 2019-10-02 Sangamo Therapeutics, Inc. Compositions pour lier des domaines de liaison à l'adn et des domaines de clivage
US11826433B2 (en) 2016-02-02 2023-11-28 University Of Massachusetts Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
LT3411484T (lt) 2016-02-05 2023-11-27 Emory University Viengrandžio arba sau pačiam komplementaraus adeno-asocijuoto viruso 9 injekcija į smegenų skystį
EP4094780A3 (fr) 2016-02-12 2023-02-08 University of Massachusetts Thérapeutiques micro-arn anti-angiogéniques pour l'inhibition de la néovascularisation de la cornée
JP7364306B2 (ja) 2016-03-31 2023-10-18 スパーク セラピューティクス インコーポレイテッド カラムに基づく高度にスケーラブルなｒＡＡＶの製造プロセス
EP3440210A4 (fr) 2016-04-05 2019-11-27 University of Massachusetts Compositions et procédés pour l'inhibition sélective de l'expression d'une protéine de type grainhead
WO2017181105A1 (fr) 2016-04-15 2017-10-19 University Of Massachusetts Méthodes et compositions pour le traitement de déséquilibres métaboliques
WO2017218852A1 (fr) 2016-06-15 2017-12-21 University Of Massachusetts Virus adéno-associés de recombinaison pour l'administration de molécules d'édition de gènes dans des cellules embryonnaires
GB201612248D0 (en) 2016-07-14 2016-08-31 Puridify Ltd New process
EP3488007B1 (fr) * 2016-07-21 2023-12-20 Spark Therapeutics, Inc. Procédés évolutifs et à haut rendement pour la production de grandes quantités de vecteur viral adéno-associé recombiné (vaar) et vecteurs viraux adéno-associés recombinés (vaar) ainsi produits
WO2018022511A1 (fr) 2016-07-25 2018-02-01 The Trustees Of The University Of Pennsylvania Compositions comprenant un variant de la lécithine-cholestérol-acyl-transférase et leurs utilisations
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
PL3504229T3 (pl) 2016-08-24 2022-04-19 Sangamo Therapeutics, Inc. Regulacja ekspresji genów przy użyciu nukleaz poddanych inżynierii
EP3504327B1 (fr) 2016-08-24 2021-10-06 Sangamo Therapeutics, Inc. Nucléases spécifiques de cible spécifiquement modifiées
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
KR20190075964A (ko) 2016-10-13 2019-07-01 유니버시티 오브 매사추세츠 Aav 캡시드 설계
JP7071348B2 (ja) * 2016-11-04 2022-05-18 武田薬品工業株式会社 アデノ随伴ウイルスの精製法
EP3321357A1 (fr) 2016-11-09 2018-05-16 Deutsches Krebsforschungszentrum Procédé évolutif de production et de purification de parvovirus oncolytique h-1 du rat à base d'élimination de particules vides par points isoélectriques
AU2018212002A1 (en) 2017-01-30 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant virus vectors for the treatment of glycogen storage disease
CA3051481A1 (fr) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Agents de ciblage de tumeur a lymphocytes t car (ctct) d'ether de phospholipide (ple)
US11554147B2 (en) 2017-02-20 2023-01-17 The Trustees Of The University Of Pennsylvania Gene therapy for treating familial hypercholesterolemia
WO2018160622A1 (fr) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions et méthodes de thérapie par lymphocytes t car
WO2018208973A1 (fr) 2017-05-09 2018-11-15 Emory University Variants du facteur de coagulation et leur utilisation
WO2018208972A1 (fr) 2017-05-09 2018-11-15 University Of Massachusetts Méthodes de traitement de la sclérose latérale amyotrophique (sla)
CA3068622A1 (fr) * 2017-06-30 2019-01-03 Spark Therapeutics, Inc. Methode de purification de colonne de vecteur aav
JP7397488B2 (ja) 2017-09-22 2023-12-13 ユニバーシティ オブ マサチューセッツ Ｓｏｄ１二重発現ベクターおよびその使用
CN111433367A (zh) 2017-10-20 2020-07-17 全国儿童医院研究所 Nt-3基因疗法的方法和材料
CA3082136A1 (fr) * 2017-11-08 2019-05-16 Avexis, Inc. Moyens et procede de preparation de vecteurs viraux et leurs utilisations
CN112055595A (zh) 2018-01-22 2020-12-08 恩多塞特公司 Car t细胞的使用方法
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
JP7244547B2 (ja) 2018-02-19 2023-03-22 ホモロジー・メディシンズ・インコーポレイテッド Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
JP7356994B2 (ja) 2018-03-02 2023-10-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 網膜炎症および神経変性を処置するためのｉｌ－３４の使用
CA3096051A1 (fr) * 2018-04-05 2019-10-10 Nightstarx Limited Compositions de vaa, procedes de preparation et methodes d'utilisation
KR20240014102A (ko) 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
AU2019323434A1 (en) 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113454226A (zh) 2018-12-18 2021-09-28 阿尔特拉吉尼克斯制药公司 用于治疗糖原贮积病的方法和组合物
JP2022516283A (ja) 2019-01-04 2022-02-25 ウルトラジェニックス ファーマシューティカル インコーポレイテッド ウイルソン病を処置するための遺伝子治療構築物
CN113474328A (zh) 2019-01-11 2021-10-01 爱康泰生治疗公司 用于脂质纳米颗粒递送活性剂的脂质
EP3990636A1 (fr) 2019-06-28 2022-05-04 CRISPR Therapeutics AG Matériels et méthodes de régulation de l'édition de gènes
CN114174514A (zh) 2019-07-25 2022-03-11 诺华股份有限公司 可调节的表达系统
WO2021062012A1 (fr) 2019-09-25 2021-04-01 Emory University Utilisation de klk10 et dérivations artificielles associées
CN113025633A (zh) 2019-12-09 2021-06-25 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
WO2021124152A1 (fr) 2019-12-19 2021-06-24 Pfizer Inc. Compositions et procédés de transfection d'acide nucléique à l'aide de polymères cationiques et de stabilisants
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
WO2021146625A1 (fr) 2020-01-17 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thérapie génique pour le traitement de rétinopathies dominantes autosomiques liées au crx
AU2021218703A1 (en) 2020-02-14 2022-07-28 Ultragenyx Pharmaceutical Inc. Gene therapy for treating CDKL5 deficiency disorder
WO2021168362A1 (fr) 2020-02-21 2021-08-26 Akouos, Inc. Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain
WO2022016070A1 (fr) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Lipides cationiques destinés à être utilisés dans des nanoparticules lipidiques
WO2022061002A1 (fr) 2020-09-18 2022-03-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nouveaux vecteurs viraux adéno-associés (vaa) pour traiter l'acidémie méthylmalonique (amm) héréditaire provoquée par une déficience en méthylmalonyl-coa mutase (mmut)
CN116406425A (zh) 2020-10-15 2023-07-07 豪夫迈·罗氏有限公司 用于va rna转录的核酸构建体
CA3198675A1 (fr) * 2020-10-15 2022-04-21 Prevail Therapeutics, Inc. Compositions de virus adeno-associes recombinants et procedes pour les produire
WO2022079082A1 (fr) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Constructions d'acides nucléiques améliorées pour activation de gènes simultanée
CN117980484A (zh) 2021-09-16 2024-05-03 诺华股份有限公司 新颖的转录因子
WO2023196898A1 (fr) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides mimétiques de la bêta globine et leur utilisation
WO2023198685A1 (fr) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Procédé de détermination de génomes d'aav
WO2023214346A1 (fr) 2022-05-06 2023-11-09 Novartis Ag Nouveaux polypeptides de fusion vp2 d'aav recombinants
WO2023227438A1 (fr) 2022-05-23 2023-11-30 F. Hoffmann-La Roche Ag Procédé raman de différenciation d'un sérotype de particules aav et d'un état de chargement de particules aav
WO2023232922A1 (fr) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Procédé de production de particules d'aav recombinées
WO2024013239A1 (fr) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Procédé de production de particules de virus adéno-associé recombinant
WO2024056561A1 (fr) 2022-09-12 2024-03-21 F. Hoffmann-La Roche Ag Procédé de séparation de particules de vaa pleines et vides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6093392A (en) * 1997-03-14 2000-07-25 Childrens Hospital Of Phildelphia Methods and compositions for use in gene therapy for treatment of hemophilia
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6491907B1 (en) * 1998-11-10 2002-12-10 The University Of North Carolina At Chapel Hill Recombinant parvovirus vectors and method of making
DK1190055T3 (da) 1999-06-30 2008-09-22 Univ Tulane Human endogen retrovirus
WO2001070763A1 (fr) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Facteurs de coagulation sanguine modifies et leur procede d'utilisation
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
AU2003253595A1 (en) * 2002-04-05 2003-11-03 The Children's Hospital Of Philadelphia Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof
SI2277996T1 (sl) * 2003-05-21 2014-12-31 Genzyme Corporation Postopki za izdelavo pripravkov rekombinantnih AAV virionov v bistvu brez praznih kapsid
JP2008501339A (ja) * 2004-06-01 2008-01-24 ジェンザイム・コーポレイション Ａａｖベクターの凝集を防ぐための組成物およびその方法
CN1873012A (zh) * 2005-06-01 2006-12-06 上海二医新生基因科技有限公司 重组腺相关病毒（rAAV）载体大规模生产新工艺
US9198984B2 (en) * 2006-04-28 2015-12-01 The Trustees Of The University Of Pennsylvania Scalable production method for AAV
WO2008128251A1 (fr) * 2007-04-17 2008-10-23 The Children's Hospital Of Philadelphia Vecteur viral humanisé et procédés pour d'utilisation
JP5615271B2 (ja) * 2008-06-18 2014-10-29 オックスフォード バイオメディカ（ユーケー）リミテッド ウイルス精製法
EP2529020B1 (fr) * 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia Plateforme de fabrication évolutive pour purification de vecteurs viraux et vecteurs viraux ainsi purifiés utilisables en thérapie génique

Also Published As

Publication number Publication date
US9408904B2 (en) 2016-08-09
CA2787827C (fr) 2020-11-10
EP2529020B1 (fr) 2018-04-25
DK2529020T3 (en) 2018-08-06
EP2529020A1 (fr) 2012-12-05
JP2018121653A (ja) 2018-08-09
AU2011209743A1 (en) 2012-08-23
JP2016185153A (ja) 2016-10-27
WO2011094198A1 (fr) 2011-08-04
US20160206706A1 (en) 2016-07-21
US10328145B2 (en) 2019-06-25
ES2680915T3 (es) 2018-09-11
US20190321463A1 (en) 2019-10-24
MX340102B (es) 2016-06-24
JP6991095B2 (ja) 2022-01-12
JP2013517798A (ja) 2013-05-20
MX2012008757A (es) 2012-11-06
IL221158B (en) 2018-07-31
AU2011209743B2 (en) 2016-03-10
BR112012018899A2 (pt) 2015-09-15
CN102947453A (zh) 2013-02-27
EP2529020A4 (fr) 2013-10-16
PT2529020T (pt) 2018-07-30
CA2787827A1 (fr) 2011-08-04
US20130072548A1 (en) 2013-03-21
JP2018046820A (ja) 2018-03-29
US11878056B2 (en) 2024-01-23
US20200405845A1 (en) 2020-12-31
CN105838737A (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
IN2012DN06629A (fr)
MY158992A (en) Forms of rifaximin and uses thereof
MX343870B (es) Compuestos que contienen mesógeno.
MX343829B (es) N-ciclilamidas como nematicidas.
MX2011003473A (es) Composiciones para el cuidado bucal.
WO2012048099A3 (fr) Cellules chargées de nanoparticules
PL2768937T3 (pl) Preparaty, ich zastosowanie jako środków do mycia naczyń lub do wytwarzania środków do mycia naczyń i ich wytwarzanie
JO3755B1 (ar) تركيبات تستوستيرون
EP2569045A4 (fr) Système à ballonnet de résection
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
MX2013008500A (es) Disialillacto-n-tetraosa (dslnt) o variantes, isomeros, analogos y derivados de la misma para prevenir o inhibir la enfermedad del intestino.
AU2011347268A8 (en) Recombinant Mycobacterium as a vaccine
IN2013MN00733A (fr)
EP2576575A4 (fr) Composés conjugués prostaglandine-bisphosphonate, leurs méthodes de fabrication et leurs utilisations
MY165088A (en) Pharmaceutical compositions comprising alisporivir
WO2012061012A3 (fr) Analogues 4-amino-2h-pyran-2-one en tant qu'agents anticancéreux
PH12014501327A1 (en) Processes for making magnolol analogs
MX2014007555A (es) Proceso para la preparacion de magnolol y derivados del mismo.
EP2471542A4 (fr) Agent thérapeutique pour maladies hépatiques
IN2015DN02818A (fr)
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
UA52529U (ru) Применение уретроскопа комбинированного (модель 513) как троакарной системы для эпицистостомии
AU2011900270A0 (en) The drac's bed tube
AU2010101240A4 (en) Blue's Mate